Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New blood test aims to catch multiple cancers early in symptomatic patients

NCT ID NCT07390643

First seen Feb 05, 2026 · Last updated Jun 23, 2026 · Updated 16 times

Summary

This study will test a blood test called GRAIL Galleri that looks for signs of many different cancers at once. Researchers will give the test to 100 adults who have symptoms that might be cancer and are already being checked by doctors. They want to see how well the test finds cancer compared to standard methods, and what types and stages of cancer it detects or misses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GRAIL Galleri MCED blood test

What this could lead to

If successful, this could show that a simple blood test helps detect various cancers earlier in people who already have symptoms, potentially improving treatment options.

What could go wrong

This is a small, early-stage study (100 participants) that has not yet started. The test may miss some cancers or give false positives, leading to unnecessary follow-up tests.

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.